Drug intelligence / Profile preview

Pecilocin

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

Pecilocin is an antimycotic antibiotic that has been used for the treatment of fungal infections, particularly those affecting the skin and nails. It exhibits antifungal activity against various yeasts and dermatophytes. Historically, it has been compared to other antifungal agents such as miconazole, nystatin, and natamycin. Allergic reactions to Pecilocin have been reported in some patients.

Brand names: Variotin
Other names: pecilocinum

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2C (5-hydroxytryptamine 2C receptor)SERT (Sodium-dependent serotonin transporter)DRD (Dopamine receptors)AR (Adrenergic receptors)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)H (Histamine receptors)

Beyond the preview

Go deeper on Pecilocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pecilocin.

Explore the full profile